Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.88 USD
-0.10 (-2.51%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.90 +0.02 (0.52%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Repare Therapeutics Inc. [RPTX]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financials; Favorable Lunresertib + Camonsertib Safety; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Roche is Gone, But ATRi Still Very Much Alive; RPTX is Trading at Half of Proforma Cash. Reinstating BUY.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Evidence Continues to Build For the Combination of an ATR inhibitor + Anti-PD1/L1 Agent
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
What to Do With Camonsertib Now That Roche Handed Back Rights; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed With Camonsertib in TAPISTRY Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Clinical Study and Collaboration Agreement Inked With Debiopharm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Two Programs Unveiled; 3Q23 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Competitor Data From ESMO Underwhelms; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Additional Combo Data in 4Q23; 2Q23 Financials; Modulating PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Initial Data From MYTHIC Trial Announced; 1Q23 Financials; Raising PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Initial Lunresertib MonoTx ORR Lite, But With Other Encouraging Signals.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
TRESR and ATTACC Trial Results Presented at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Repare Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Camonsertib+PARPi: Encouraging Early Results in Heavily Pre-treated Patients.
Provider: Bloom Burton & Company
Analyst: MARTIN D